Table 3.
Treatment-related adverse events (AEs) observed during the therapeutic Part
| Arm A - 370 MBq | Arm B - 1110 MBq | |||
|---|---|---|---|---|
| N = 3 | N = 5 | |||
| Patients | Patients | |||
| N | % | N | % | |
| All treatment-related AEs | 3 | (100.0%) | 4 | (80.0%) |
| Lymphopenia | 3 | (100.0%) | 4 | (80.0%) |
| Anemia | 3 | (100.0%) | 3 | (60.0%) |
| Leucopenia | 1 | (33.3%) | 4 | (80.0%) |
| Asthenia | 2 | (66.7%) | 2 | (40.0%) |
| Hemoptysis | 1 | (33.3%) | 3 | (60.0%) |
| Thrombopenia | 1 | (33.3%) | 3 | (60.0%) |
| Neutropenia | 0 | (0.0%) | 3 | (60.0%) |
| Anorexia | 2 | (66.7%) | 0 | (0.0%) |
| Creatinine increased | 0 | (0.0%) | 2 | (40.0%) |
| Hypokalemia | 1 | (33.3%) | 1 | (20.0%) |
| Nausea | 1 | (33.3%) | 1 | (20.0%) |
| Hypoalbuminemia | 1 | (33.3%) | 0 | (0.0%) |
| Hypophosphatemia | 0 | (0.0%) | 1 | (20.0%) |
| Hypoxemia | 0 | (0.0%) | 1 | (20.0%) |
| Vomiting | 1 | (33.3%) | 0 | (0.0%) |
| Weight loss | 1 | (33.3%) | 0 | (0.0%) |
| All treatment-related AE ≥ Grade 3 | 1 | (33.3%) | 4 | (80.0%) |
| Lymphopenia | 0 | (0.0%) | 3 | (60.0%) |
| Thrombopenia | 1 | (33.3%) | 2 | (40.0%) |
| Anemia | 1 | (33.3%) | 1 | (20.0%) |
| Neutropenia | 0 | (0.0%) | 2 | (40.0%) |
| Asthenia | 1 | (33.3%) | 0 | (0.0%) |
| Hemoptysis | 0 | (0.0%) | 1 | (20.0%) |
| Hypoxemia | 0 | (0.0%) | 1 | (20.0%) |
| Leucopenia | 0 | (0.0%) | 1 | (20.0%) |